This trial is now complete.
The PROMISE trial was the largest yet trial into treating unexplained recurrent miscarriage with progesterone. It was led by Professor Arri Coomarasamy, Director of the Tommy’s National Centre for Miscarriage Research.
Recurrent miscarriage, the loss of 3 or more pregnancies in a row, affects around 1% of couples. Even after investigations, most do not get a cause for their losses. Alongside the physical trauma of repeated miscarriages, this can have severe consequences for mental health and relationships.
The role of progesterone in early pregnancy
Progesterone is a hormone that is released naturally by the female body in the the second half of the menstrual cycle in early pregnancy. Progesterone prepares the lining of the womb for implantation of the embryo.
If implantation happens, progesterone continues to be produced, and at between 8 and 12 weeks of gestation, the placenta takes over the role of producing progesterone and maintains the pregnancy from there on.
Previous research into progesterone supplementation in early pregnancy
The clear importance of progesterone in early pregnancy has prompted a number of research trials to evaluate the effect of progesterone supplementation in the first trimester of pregnancy among women with a history of recurrent miscarriages.
A Cochrane review of four small trials showed a significantly lower risk of miscarriages among women who received progesterone than among those who received placebo or no treatment. The results were exciting but unfortunately the quality of the four trials was considered to be poor.
The PROMISE trial design
In response Professor Coomarasamy designed PROMISE, very high quality a multi-centre, randomised, placebo-controlled trial to see if he could replicate these findings.
- Women had to have had 3 or more unexplained miscarriages.
- Those who took part were randomly given vaginal suppositories twice daily containing either 400 mg of micronized progesterone (Utrogestan, Besins Healthcare) or a similar-looking placebo.
- They started taking them from a time soon after getting a positive pregnancy test (and no later than 6 weeks of pregnancy) through 12 weeks.
- 836 women who had signed up to the trial and conceived naturally within a year took part in the PROMISE trial.
Results of PROMISE
A successful outcome was considered to be a live birth after 24 weeks of gestation.
- For those who received progesterone, it was was 65.8% (262 of 398 pregnancies) in the progesterone group
- For those got the placebo, it was 63.3% (271 of 428 pregnancies).
The difference between the groups was not statistically significant and these results did NOT support the earlier smaller trials. Progesterone was not shown to reduce the risk of another miscarriage in those who have suffered recurrent losses.
Although the results are disappointing, it is helpful after many years of uncertainty, for health professionals to know that progesterone treatment in early pregnancy isn’t the answer for women with unexplained recurrent losses.
The trial did not show that supplementing with progesterone was in any way harmful in pregnancy.
The clear results also mean that researchers can focus on looking at new reasons and treatments.
Professor Coomarasamy and his team have started another trial called PRISM, investigating the role of progesterone in a new group, those who have vaginal bleeding in early pregnancy. This trial is due to report in 2019.
More miscarriage research projects
Natalie and Sean from Warwickshire were delighted when the found out that they were expecting twins. At 25 weeks pregnant, Natalie went into premature labour. Their daughters, Daisy and Georgie, passed away soon after birth. Natalie went on to have 2 heart-breaking miscarriages before getting support from Tommy’s National Centre for Miscarriage Research. Their rainbow baby Livvie was born in 2019.
Leanne and Kieran experienced a heart-breaking missed miscarriage before the arrival of their first daughter, Rosa. Sadly, they went on to experience another miscarriage before getting referred to Tommy’s National Centre for Miscarriage Research at Birmingham Women’s Hospital. During Leanne’s next pregnancy, she was supported by the team at our recurrent miscarriage clinic. Their second healthy baby, Pearl, was born in October 2019.
In this honest and raw account of miscarriage, Lizzie reflects on her experience and the vast array of emotions she has felt since losing 2 precious babies earlier this year. She also explores the devastating impact that baby loss can have on relationships with family and friends.
After a smooth pregnancy and labour with her son, Alice and her husband Brian hoped to give Frankie a sibling but were heartbroken by the shock of a missed miscarriage. In this blog, Alice reflects on the complex feelings of grief and guilt, and the support that has helped her to cope with the loss.
A BBC News investigation has found that some private baby scanning studios are misleading customers by advertising “reassurance” scans that do not diagnose serious conditions and abnormalities.
In this Q&A, we sit down and chat with with Tom Willmott, a researcher based at Tommy’s Maternal and Fetal Health Research Centre in Manchester. He gives a rare insight into a novel and exciting area of pregnancy health research, known as ‘maternal microbiology’, looking at what we can learn by studying bacteria in the mouths of mums-to-be.
A recently published article, co-authored by Professor Catherine Williamson from Tommy’s Research Centre at King’s College London, suggests that certain pregnancy complications can indicate future health issues for women.
Tommy’s has received a grant from the UK Government’s Department for Health and Social Care to support the costs of its PregnancyHub information and support services throughout the summer, due to rising demand in the wake of coronavirus.